Elisa Colangelo

David J. Muzina, MD
Vice Chair for Research and Education, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

Elisa Colangelo
Research Assistant, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

J. Sloan Manning, MD
Family Physician, Greensboro, NC

Joseph R. Calabrese, MD
Professor of Psychiatry; Co-Director, Bipolar Disorders Research Center, Case Western Reserve University School of Medicine; Director, Mood Disorders Program, University Hospitals of Cleveland

Address: David J. Muzina, MD, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria for teaching, speaking, consulting, or serving on advisory committees or review panels for the AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer corporations.

Dr. Manning has disclosed receiving honoraria for teaching, speaking, and consulting for the AstraZeneca and Eli Lilly corporations.

Dr. Calabrese has disclosed that he has received honoraria, consulting fees, or research support from Abbott Pharmaceuticals, AstraZeneca, Bristol Myers Squibb/Otsuka, Ciba-Geigy, Eli Lilly, GlaxoSmithKline, Janssen, MacArthur Foundation, Merck, National Alliance for Research in Schizophrenia and Affective Disorders, National Institutes of Mental Health, Novartis, Parke Davis/Warner Lambert, Robert Wood Johnson Pharmaceutical Research Institute, Sandoz, Shire Laboratories, SmithKline Beecham, Stanley Foundation, TAP Holdings, Teva Pharmaceuticals, UCB Pharma, and Wyeth Ayerst Pharmaceuticals.

David J. Muzina, MD
Vice Chair for Research and Education, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

Elisa Colangelo
Research Assistant, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

J. Sloan Manning, MD
Family Physician, Greensboro, NC

Joseph R. Calabrese, MD
Professor of Psychiatry; Co-Director, Bipolar Disorders Research Center, Case Western Reserve University School of Medicine; Director, Mood Disorders Program, University Hospitals of Cleveland

Address: David J. Muzina, MD, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria for teaching, speaking, consulting, or serving on advisory committees or review panels for the AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer corporations.

Dr. Manning has disclosed receiving honoraria for teaching, speaking, and consulting for the AstraZeneca and Eli Lilly corporations.

Dr. Calabrese has disclosed that he has received honoraria, consulting fees, or research support from Abbott Pharmaceuticals, AstraZeneca, Bristol Myers Squibb/Otsuka, Ciba-Geigy, Eli Lilly, GlaxoSmithKline, Janssen, MacArthur Foundation, Merck, National Alliance for Research in Schizophrenia and Affective Disorders, National Institutes of Mental Health, Novartis, Parke Davis/Warner Lambert, Robert Wood Johnson Pharmaceutical Research Institute, Sandoz, Shire Laboratories, SmithKline Beecham, Stanley Foundation, TAP Holdings, Teva Pharmaceuticals, UCB Pharma, and Wyeth Ayerst Pharmaceuticals.

David J. Muzina, MD
Vice Chair for Research and Education, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

Elisa Colangelo
Research Assistant, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic

J. Sloan Manning, MD
Family Physician, Greensboro, NC

Joseph R. Calabrese, MD
Professor of Psychiatry; Co-Director, Bipolar Disorders Research Center, Case Western Reserve University School of Medicine; Director, Mood Disorders Program, University Hospitals of Cleveland

Address: David J. Muzina, MD, Director, Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, P57, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: muzinad@ccf.org

Dr. Muzina has disclosed that he has received honoraria for teaching, speaking, consulting, or serving on advisory committees or review panels for the AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer corporations.

Dr. Manning has disclosed receiving honoraria for teaching, speaking, and consulting for the AstraZeneca and Eli Lilly corporations.

Dr. Calabrese has disclosed that he has received honoraria, consulting fees, or research support from Abbott Pharmaceuticals, AstraZeneca, Bristol Myers Squibb/Otsuka, Ciba-Geigy, Eli Lilly, GlaxoSmithKline, Janssen, MacArthur Foundation, Merck, National Alliance for Research in Schizophrenia and Affective Disorders, National Institutes of Mental Health, Novartis, Parke Davis/Warner Lambert, Robert Wood Johnson Pharmaceutical Research Institute, Sandoz, Shire Laboratories, SmithKline Beecham, Stanley Foundation, TAP Holdings, Teva Pharmaceuticals, UCB Pharma, and Wyeth Ayerst Pharmaceuticals.